CurrentCardio
Get Weekly

General medical journalCurrentCardio coverage

The Lancet

What CurrentCardio has captured from this journal. The coverage figures describe CurrentCardio's coverage, not the journal's output. Figures as of 13 October 2026.

Recent
10 Briefs
past 90 days
Archive
84 Briefs
research published Apr 2023 – Sep 2026
Editorial
–
no Weekly issue published yet
Impact Factor
109.0
2025 · Journal Citation Reports

Topics

Evidence types

Shares are of the 84 Briefs CurrentCardio has covered from Lancet, by primary topic and study type; a Brief without a primary topic is in no topic row.

Publication activity

Latest from The Lancet

All coverage, newest first

  1. Lancet

    Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial

    Randomised controlled trialCardiometabolic & kidney

  2. Lancet

    Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark

    Randomised controlled trialHeart failure

  3. Lancet

    Aetiology, management, and outcomes of acute heart failure in 17 African countries (THESUS-HF II): a prospective, multicentre, observational cohort study

    Cohort studyHeart failure

  4. Lancet

    Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial

    Randomised controlled trialArrhythmias & EP

  5. Lancet

    Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data

    Meta-analysisCoronary & ACS

  6. Lancet

    Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial

    Randomised controlled trialCoronary & ACS

  7. Lancet

    Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

    Randomised controlled trialPrevention & lipids

  8. Lancet

    Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial

    Randomised controlled trialCoronary & ACS

  9. Lancet

    Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study

    Randomised controlled trialPulmonary vascular & VTE

  10. Lancet

    1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial

    Randomised controlled trialCoronary & ACS

  11. Lancet

    Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial

    Randomised controlled trialAcute care & resuscitation

  12. Lancet

    Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies

    Meta-analysisCardiometabolic & kidney

  13. Lancet

    Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study

    Randomised controlled trialHeart failure

  14. Lancet

    Coronary microvascular dysfunction and cardiovascular outcomes (Multicenter FLOW-CMD Registry): a prospective, multicentre cohort study in South Korea

    Cohort studyCoronary & ACS

  15. Lancet

    Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis

    Meta-analysisCardiometabolic & kidney

  16. Lancet

    Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial

    Randomised controlled trialCoronary & ACS

  17. Lancet

    Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial

    Randomised controlled trialValvular & structural

  18. Lancet

    Angiography-derived fractional flow reserve versus coronary angiography to guide coronary artery bypass grafting in patients undergoing surgical valve procedures with concomitant coronary artery disease in China (FAVOR IV-QVAS): a multicentre, triple-blind, randomised trial

    Randomised controlled trialCoronary & ACS

  19. Lancet

    Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial

    Randomised controlled trialHypertension

  20. Lancet

    Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study

    Diagnostic or prognostic studyCoronary & ACS

  21. Lancet

    Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial

    Randomised controlled trialHeart failure

  22. Lancet

    Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial

    Randomised controlled trialCoronary & ACS

  23. Lancet

    Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study

    Cohort studyValvular & structural

  24. Lancet

    Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials

    Meta-analysisCoronary & ACS

  25. Lancet

    Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials

    Randomised controlled trialPulmonary vascular & VTE

  26. Lancet

    Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial

    Randomised controlled trialCoronary & ACS

  27. Lancet

    Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

    Secondary analysisCardiometabolic & kidney

  28. Lancet

    Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial

    Randomised controlled trialCoronary & ACS

  29. Lancet

    Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION–STEMI): a multicentre, non-inferiority, open-label, randomised trial

    Randomised controlled trialCoronary & ACS

  30. Lancet

    Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial

    Randomised controlled trialAortic & peripheral

  31. Lancet

    Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial

    Randomised controlled trialAortic & peripheral

  32. Lancet

    Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China

    Randomised controlled trialHeart failure

  33. Lancet

    Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

    Randomised controlled trialHeart failure

  34. Lancet

    Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials

    Meta-analysisHypertension

  35. Lancet

    Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials

    Meta-analysisCardiometabolic & kidney

  36. Lancet

    Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis

    Meta-analysisCardiometabolic & kidney

  37. Lancet

    Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial

    Randomised controlled trialCardiometabolic & kidney

  38. Lancet

    ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial

    Randomised controlled trialValvular & structural

  39. Lancet

    Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial

    Randomised controlled trialPrevention & lipids

  40. Lancet

    SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial

    Randomised controlled trialValvular & structural

All 84 Briefs in ExploreShowing the 40 most recently published